Femasys (NASDAQ:FEMY) Upgraded by Wall Street Zen to “Hold” Rating

Femasys (NASDAQ:FEMY) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday.

FEMY has been the topic of a number of other reports. Laidlaw assumed coverage on shares of Femasys in a research note on Thursday, November 20th. They issued a “buy” rating and a $6.50 price target on the stock. HC Wainwright lowered their price objective on shares of Femasys from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Monday, August 11th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Femasys in a research report on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $6.83.

Femasys Stock Performance

Shares of Femasys stock opened at $1.02 on Friday. The firm has a market cap of $59.36 million, a PE ratio of -1.41 and a beta of -2.55. The company has a quick ratio of 0.61, a current ratio of 1.16 and a debt-to-equity ratio of 0.01. Femasys has a 52 week low of $0.31 and a 52 week high of $1.80. The business’s fifty day simple moving average is $0.69 and its 200-day simple moving average is $0.75.

Femasys (NASDAQ:FEMY) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.02. Femasys had a negative net margin of 960.80% and a negative return on equity of 764.26%. The firm had revenue of $0.73 million for the quarter, compared to analyst estimates of $1.35 million. Equities analysts forecast that Femasys will post -0.86 earnings per share for the current year.

Hedge Funds Weigh In On Femasys

Several hedge funds and other institutional investors have recently added to or reduced their stakes in FEMY. Clear Creek Financial Management LLC increased its position in shares of Femasys by 4.2% during the second quarter. Clear Creek Financial Management LLC now owns 281,821 shares of the company’s stock worth $272,000 after acquiring an additional 11,450 shares during the period. Osaic Holdings Inc. purchased a new position in Femasys in the second quarter valued at $45,000. Finally, Jane Street Group LLC acquired a new position in Femasys during the 2nd quarter worth $82,000. Hedge funds and other institutional investors own 65.27% of the company’s stock.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.